Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Senti Biosciences (SNTI) Enterprise Value (2021 - 2025)

Senti Biosciences has reported Enterprise Value over the past 5 years, most recently at -$16.4 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 65.99% year-over-year to -$16.4 million; the TTM value through Dec 2025 reached -$16.4 million, up 65.99%, while the annual FY2025 figure was -$16.4 million, 65.99% up from the prior year.
  • Enterprise Value for Q4 2025 was -$16.4 million at Senti Biosciences, down from -$12.2 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$10.5 million in Q3 2024 and troughed at -$139.8 million in Q2 2022.
  • A 5-year average of -$52.5 million and a median of -$39.4 million in 2023 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: crashed 99.54% in 2023 and later surged 73.42% in 2024.
  • Year by year, Enterprise Value stood at -$56.0 million in 2021, then tumbled by 75.9% to -$98.6 million in 2022, then skyrocketed by 63.58% to -$35.9 million in 2023, then crashed by 34.48% to -$48.3 million in 2024, then soared by 65.99% to -$16.4 million in 2025.
  • Business Quant data shows Enterprise Value for SNTI at -$16.4 million in Q4 2025, -$12.2 million in Q3 2025, and -$21.6 million in Q2 2025.